Iridex (IRIX) Asset Writedowns and Impairment (2011 - 2025)

Iridex (IRIX) posted Asset Writedowns and Impairment of $800000.0 for Q3 2025, up 892.08% on a QoQ basis from -$101000.0 in Q1 2022.

Analysis

Iridex (IRIX) Asset Writedowns and Impairment (2011 - 2025) Analysis & Trends

Iridex has reported Asset Writedowns and Impairment for 11 years, with the latest figure at $800000.0 in Q3 2025.

On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $800000.0 in Q3 2025; TTM through Jan 2026 was $800000.0, a 1350.0% increase from a year earlier, with the FY2026 full-year figure at $823000.0, changed N/A from the prior year.
Asset Writedowns and Impairment was $800000.0 for Q3 2025 at Iridex, up from -$101000.0 in the prior quarter.
The five-year high for Asset Writedowns and Impairment was $800000.0 in Q3 2025, with the low at -$101000.0 in Q1 2022.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	183.04 Bn	177.44 Bn	7.27 Bn
2	Intuitive Surgical	125.02 Bn	119.81 Bn	1.96 Bn
3	Medtronic	117.84 Bn	109.02 Bn	6.34 Bn
4	Stryker	105.50 Bn	102.02 Bn	4.50 Bn
5	Boston Scientific	66.27 Bn	65.73 Bn	3.85 Bn
6	Edwards Lifesciences	49.60 Bn	45.35 Bn	1.35 Bn
7	Alcon	33.70 Bn	32.24 Bn	1.68 Bn
8	Dexcom	32.06 Bn	30.11 Bn	830.00 Mn
9	Steris	21.02 Bn	20.54 Bn	684.20 Mn
10	Iridex	11.85 Mn	7.17 Mn	4.30 Mn

Historic Data

Download Data